First-pass extracted concept

GenE-HumDi

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

Genome editing for the treatment of human disease

Extracted Explainers

What the tool is doing

GenE-HumDi is presented as an EU-funded COST Action that builds feedback networks to accelerate and harmonize approval of genome-editing therapies. It supports meetings, courses, and mobility to connect stakeholders across the translational pipeline.

Source 1DOI PubMed

Resources required

The abstract indicates that the network operates through grants, educational activities, conferences, meetings, and participation from academic, industrial, and healthcare partners.

Source 1DOI PubMed

What problem it solves

It addresses the need for coordination and harmonization in the development and approval of genome-editing medicines.

Source 1DOI PubMed

What it does not solve

The abstract does not present GenE-HumDi as a specific genome-editing reagent, delivery system, or assay for direct experimental use.

Source 1DOI PubMed

Alternatives

No direct alternative networks or programs are named in the provided source.

Source 1DOI PubMed

Evidence Snippets

Genome editing for the treatment of human disease (GenE-HumDi) is an EU-funded COST Action for the development and consolidation of academic, industrial and healthcare feedback networks aiming to accelerate, foster and harmonize the approval of genome-editing (GE) therapies.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1meeting conclusionsupports2025Source 1DOI PubMed

The second annual GenE-HumDi meeting identified action priorities and gaps in knowledge, standardization, and dissemination for new genome-editing tools, delivery methods, safety monitoring, validation for clinical use, industrial manufacturing, and regulatory issues.

Claim 2meeting scopesupports2025Source 1DOI PubMed

The conclusions of the second annual GenE-HumDi meeting are intended to guide genome-editing application in Europe through coordination, enhanced collaboration, and focus on critical developments.

Claim 3program activitysupports2025Source 1DOI PubMed

GenE-HumDi supports mobility grants, educational courses, conferences, and meetings to promote synergistic interactions across discovery, validation, optimization, manufacturing, and clinical application of genomic medicines.

Claim 4program objectivesupports2025Source 1DOI PubMed

GenE-HumDi aims to accelerate, foster, and harmonize the approval of genome-editing therapies through development and consolidation of academic, industrial, and healthcare feedback networks.